HomeCompareGBLP vs BTI

GBLP vs BTI: Dividend Comparison 2026

GBLP yields 4000.00% · BTI yields 5.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GBLP wins by $7175340620755.83M in total portfolio value
10 years
GBLP
GBLP
● Live price
4000.00%
Share price
$0.05
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7175340620755.87M
Annual income
$6,839,006,593,197,835,000.00
Full GBLP calculator →
BTI
BTI
● Live price
5.38%
Share price
$58.47
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.7K
Annual income
$2,786.64
Full BTI calculator →

Portfolio growth — GBLP vs BTI

📍 GBLP pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGBLPBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GBLP + BTI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GBLP pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GBLP
Annual income on $10K today (after 15% tax)
$340,000.00/yr
After 10yr DRIP, annual income (after tax)
$5,813,155,604,218,160,000.00/yr
BTI
Annual income on $10K today (after 15% tax)
$457.40/yr
After 10yr DRIP, annual income (after tax)
$2,368.64/yr
At 15% tax rate, GBLP beats the other by $5,813,155,604,218,158,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GBLP + BTI for your $10,000?

GBLP: 50%BTI: 50%
100% BTI50/50100% GBLP
Portfolio after 10yr
$3587670310377.95M
Annual income
$3,419,503,296,598,919,000.00/yr
Blended yield
95.31%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

GBLP
No analyst data
Altman Z
-6.7
Piotroski
3/9
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.6% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GBLP buys
0
BTI buys
0
No recent congressional trades found for GBLP or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGBLPBTI
Forward yield4000.00%5.38%
Annual dividend / share$2.00$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3%
Portfolio after 10y$7175340620755.87M$37.7K
Annual income after 10y$6,839,006,593,197,835,000.00$2,786.64
Total dividends collected$7152397773804.84M$14.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: GBLP vs BTI ($10,000, DRIP)

YearGBLP PortfolioGBLP Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$410,700$400,000.00$11,299$598.92+$399.4KGBLP
2$15,792,720$15,353,271.03$12,794$703.91+$15.78MGBLP
3$568,657,142$551,758,931.89$14,518$829.07+$568.64MGBLP
4$19,176,207,860$18,567,744,718.20$16,513$978.64+$19176.19MGBLP
5$605,696,028,890$585,177,486,479.73$18,827$1,157.84+$605696.01MGBLP
6$17,922,210,653,594$17,274,115,902,681.27$21,518$1,373.12+$17922210.63MGBLP
7$496,869,793,504,300$477,693,028,104,954.00$24,657$1,632.46+$496869793.48MGBLP
8$12,908,672,105,251,704$12,377,021,426,202,104.00$28,329$1,945.74+$12908672105.22MGBLP
9$314,330,866,876,668,540$300,518,587,724,049,200.00$32,637$2,325.33+$314330866876.64MGBLP
10$7,175,340,620,755,871,000$6,839,006,593,197,835,000.00$37,708$2,786.64+$7175340620755.83MGBLP

GBLP vs BTI: Complete Analysis 2026

GBLPStock

Global Pharmatech, Inc. engages in the research, production, and development of herbal medicine, bio-medicine, chemical medicine, traditional chinese medicine, and dietary supplements primarily in China. The company's principal product line consists of XS CAPSULE (XIN-SHU) for the treatment of angina and other coronary disease; JUTAI SOFT CAPSULE, a dietary supplement; QINGXUAN ANTI-HYPERTENSION TABLET, an over-the-counter drug product indicated for the treatment of hypertension and high serum cholesterol level; and YANREQING TABLET for the treatment of inflammation. It also manufactures and sells other proprietary drugs, generics, and dietary supplements used to treat symptoms ranging from headaches, coughing, and dry mouth to infections, and numbness of limbs. The company markets its products through distributors, such as wholesale companies and chain store representatives, as well as through its sales force. Global Pharmatech, Inc. was founded in 2001 and is based in Changchun, China.

Full GBLP Calculator →

BTIConsumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this GBLP vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GBLP vs SCHDGBLP vs JEPIGBLP vs OGBLP vs KOGBLP vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.